Predicting tumor progression in lung cancer patients
CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer
This study is testing new blood markers in patients with early-stage lung cancer to see if they can help predict if the cancer will spread, so doctors can create better follow-up plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Bron) |
| Trial ID | NCT02764606 on ClinicalTrials.gov |
What this trial studies
CANPOS is an observational study that evaluates new serum markers at the time of initial surgery to predict the occurrence of metastases in patients with early-stage non-small cell lung cancer. By analyzing serum and plasma samples, the study aims to develop personalized follow-up and prevention strategies for these patients. This non-interventional approach focuses on patients who are newly diagnosed and have not received any oncology treatment within the past five years.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a diagnosis or suspicion of non-small cell lung cancer who have not undergone any oncology treatment in the past five years.
Not a fit: Patients currently undergoing cancer treatment or with a history of cancer within the last five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved personalized treatment plans and monitoring for lung cancer patients.
How similar studies have performed: Other studies have explored predictive biomarkers in lung cancer, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with a diagnosis or suspected for a diagnosis of lung cancer, non-small cell lung cancer * age over 18 years * patient naïve of any oncology treatment (excluding surgery alone) within the past 5 years * patient who signed the informed consent by the study protocol Exclusion criteria were: * any ongoing treatment for cancer * any history of cancer within 5 years before the diagnosis of lung cancer * any psychological, sociological or geographical conditions that would not allow the study follow-up
Where this trial is running
Bron
- Hospices Civils de Lyon / Hôpital Neurologique Pierre Wertheimer — Bron, France (Recruiting)
Study contacts
- Study coordinator: Nicolas Girard
- Email: nicolas.girard@chu-lyon.fr
- Phone: +33427857700
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.